Summary | |
---|---|
Symbol | IRF2 |
Name | interferon regulatory factor 2 |
Aliases | IRF-2 |
Chromosomal Location | 4q34.1-q35.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Nucleus. |
Domain |
PF00605 Interferon regulatory factor transcription factor |
Function |
Specifically binds to the upstream regulatory region of type I IFN and IFN-inducible MHC class I genes (the interferon consensus sequence (ICS)) and represses those genes. Also acts as an activator for several genes including H4 and IL7. Constitutively binds to the ISRE promoter to activate IL7. Involved in cell cycle regulation through binding the site II (HiNF-M) promoter region of H4 and activating transcription during cell growth. Antagonizes IRF1 transcriptional activation. |
Biological Process |
GO:0007596 blood coagulation GO:0007599 hemostasis GO:0034340 response to type I interferon GO:0034341 response to interferon-gamma GO:0050817 coagulation GO:0050878 regulation of body fluid levels GO:0060333 interferon-gamma-mediated signaling pathway GO:0060337 type I interferon signaling pathway GO:0071346 cellular response to interferon-gamma GO:0071357 cellular response to type I interferon |
Molecular Function |
GO:0001228 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding |
Cellular Component |
GO:0005924 cell-substrate adherens junction GO:0005925 focal adhesion GO:0030055 cell-substrate junction |
KEGG | - |
Reactome |
R-HSA-1280215: Cytokine Signaling in Immune system R-HSA-983231: Factors involved in megakaryocyte development and platelet production R-HSA-109582: Hemostasis R-HSA-168256: Immune System R-HSA-168249: Innate Immune System R-HSA-913531: Interferon Signaling R-HSA-909733: Interferon alpha/beta signaling R-HSA-877300: Interferon gamma signaling R-HSA-168928: RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways R-HSA-933541: TRAF6 mediated IRF7 activation |
Summary | |
---|---|
Symbol | IRF2 |
Name | interferon regulatory factor 2 |
Aliases | IRF-2 |
Chromosomal Location | 4q34.1-q35.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between IRF2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
Literatures describing the relation between IRF2 and anti-tumor immunity in human cancer.
|
Summary | |
---|---|
Symbol | IRF2 |
Name | interferon regulatory factor 2 |
Aliases | IRF-2 |
Chromosomal Location | 4q34.1-q35.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of IRF2 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | IRF2 |
Name | interferon regulatory factor 2 |
Aliases | IRF-2 |
Chromosomal Location | 4q34.1-q35.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of IRF2 in various data sets.
|
Points in the above scatter plot represent the mutation difference of IRF2 in various data sets.
|
Summary | |
---|---|
Symbol | IRF2 |
Name | interferon regulatory factor 2 |
Aliases | IRF-2 |
Chromosomal Location | 4q34.1-q35.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of IRF2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | IRF2 |
Name | interferon regulatory factor 2 |
Aliases | IRF-2 |
Chromosomal Location | 4q34.1-q35.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of IRF2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by IRF2. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | IRF2 |
Name | interferon regulatory factor 2 |
Aliases | IRF-2 |
Chromosomal Location | 4q34.1-q35.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of IRF2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | IRF2 |
Name | interferon regulatory factor 2 |
Aliases | IRF-2 |
Chromosomal Location | 4q34.1-q35.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of IRF2 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | IRF2 |
Name | interferon regulatory factor 2 |
Aliases | IRF-2 |
Chromosomal Location | 4q34.1-q35.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between IRF2 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |